Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/SFDA/TRIVACIN 4.6MG/24H TRANSDERMAL PATCHES

Authorized

GENERIC

TRIVACIN 4.6MG/24H TRANSDERMAL PATCHES

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: f1911684f7ef59f5
Company: Unknown
Type: Generic

Approval Details

Approval Id: f1911684f7ef59f5
Drug Approval Sfda Name: TRIVACIN 4.6MG/24H TRANSDERMAL PATCHES
Trade Name: TRIVACIN 4.6MG/24H TRANSDERMAL PATCHES
Generic Name: RIVASTIGMINE
Register Number: 7-5328-20
Register Year: 2020
Drug Type: Generic
Route Of Administration: Transdermal use
Package Type: Pouch
Package Size: 30
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: do not store above 30°c
Shelf Life: 24 Months
Distribution Site: Pharmacy
Description Code: 7000001113-9-100000073741
Price: 166.95

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

f1911684f7ef59f5

Type

Generic

Back to SFDA Approvals

TRIVACIN 4.6MG/24H TRANSDERMAL PATCHES - SFDA Drug Approval Details